Improved Membrane Chromatography Performance
![](/46/pdcnewsitem/03/47/96/7x7gCJ5LM24ULPo.jpg)
To more effectively recover large molecular weight proteins, such as blood factors and conjugated proteins or viruses and virus-like particles, Sartorius Stedim Biotech (SSB) has reconfigured its Sartobind membrane chromatography capsules. A range of capsule sizes with a 4 mm bed height is now available from the 1 mL
nano unit up to the new 2.5 L jumbo version.
The capsules’ upstream flow channels have been optimized, and an internal core forms a miniaturized downstream channel, resembling that in existing 8 mm bed height capsules. The new Q, S and salt-tolerant STIC PA ion exchanger capsules, all with a 4 mm bed height, increase dynamic binding capacity by approximately 15% and reduce void volumes by approximately 40% compared with their predecessors, while maintaining high flow rates of 10–30 membrane volumes per minute.
By improving breakthrough behavior, subsequent polishing steps to remove DNA, HCP, aggregates and viruses from recombinant proteins are significantly more reliable and, as less buffer is used, Sartobind also reduces operational costs.
“Traditionally, membrane adsorbers have been using available filter housings, often ignoring chromatographic process parameters, such as back-mixing effects and elution volumes. This new generation of membrane adsorber capsules takes these specific requirements into account and reflects substantial progress for bind and elute applications,” commented Dr Fischer-Frühholz, membrane chromatography expert at SSB.
Furthermore, SSB has added new 400 mL and 800 mL Sartobind Q, S and Phenyl capsules with an 8 mm bed height to its portfolio. These optimized capsules increase dynamic binding capacity up to 48% when compared to adsorbers installed in filter housings.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance